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Dynamics of the serologic response in vaccinated
and unvaccinated mumps cases during
an epidemic
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Erasmus University Medical Center; Rotterdam, the Netherlands
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Abbreviations: MMR, measles mumps and rubella; ND50, reciprocal virus-neutralizing antibody dose; VN, virus-neutralizing
antibody; RU/ml, RIVM units per ml; GMC, geometric mean concentration; 95% CI, lower and upper 95% confidence
intervals of GMC
In the last decade, several mumps outbreaks were reported in various countries despite high vaccination coverage.
In most cases, young adults were affected who have acquired immunity against mumps solely by vaccination and not
by previous wild-type mumps virus infection. To investigate mumps-speciﬁc antibody levels, functionality and
dynamics during a mumps epidemic, blood samples were obtained longitudinally from 23 clinical mumps cases, with or
without a prior history of vaccination, and from 20 healthy persons with no serological evidence of recent mumps virus
infection. Blood samples from mumps cases were taken 1–2 months and 7–10 months after onset of disease. Both
vaccinated and unvaccinated mumps cases had signiﬁcantly higher geomean concentrations of mumps-speciﬁc IgG
(resp. 13,617 RU/ml (95% CI of 9,574–19,367 RU/ml) vs. 1,552 (445–5412) RU/ml at 1–2 months; and 6,514 (5,247–8,088)
RU/ml vs. 1,143 (480–2,725) RU/ml at 7–10 months) than healthy controls (169 (135–210) RU/ml) (pD 0.001). Patterns in
virus-neutralizing (VN) antibody responses against the mumps vaccine virus were similar, vaccinated and unvaccinated
mumps cases had signiﬁcantly higher ND50 values at both time points of sampling (resp 4,695 (3,779–5,832) RU/ml vs.
1,533 (832–2,825) RU/ml at 1–2 months; 2,478 (1,968–3,122) RU/ml vs. 1,221 (1,029–1,449) RU/ml at 7–10 months)
compared with (previously vaccinated) healthy controls (122 (196–76)) RU/ml) (pD 0.001) The unvaccinated mumps
cases had signiﬁcantly lower mumps-speciﬁc IgG and VN antibody concentrations at both sampling points compared
with previously vaccinated cases, but their antibody concentrations did not differ signiﬁcantly at the 2 time points. In
contrast, the mumps-speciﬁc IgG and VN antibody concentrations of the previously vaccinated mumps cases were
signiﬁcantly higher within the ﬁrst 2 months after onset of mumps and declined thereafter, characteristic for a
secondary response. A moderate correlation was found between the level of mumps-speciﬁc IgG serum antibodies and
VN antibodies for the mumps cases (r D 0.64; p<0.001).
Introduction
Most countries have incorporated mumps vaccination into
their national immunization programs by the implementation of
the combined measles, mumps and rubella (MMR) vaccine.1 In
the Netherlands, MMR vaccination was implemented in 1987
by offering vaccinations to children at the age of 14 months and
9 y As a consequence, the annual mumps incidence decreased
dramatically as in other countries where mumps vaccination
was implemented.2,3 Although it was assumed that mumps
vaccination induces life-long protection,4 several mumps out-
breaks, especially among vaccinated student populations, have
been reported during the last decade in various countries where
mumps vaccination has been implemented into their national
immunization programs.5-14 In 2009–2012, a mumps epidemic
(genotype G) arose that spread across multiple locations within
the Netherlands, in which also primarily vaccinated students
were affected.15 Waning of vaccine-induced immunity has been
suggested to play a role in these outbreaks.6-10,13,14 When com-
pared to the other components in the MMR vaccine, the mumps
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component seemed to be the least effective in eliciting good (high
avidity) antibody responses, which were shown to wane to lower
levels and in avidity index 20 y after a second MMR vaccina-
tion.16 Furthermore, vaccine-induced antibody concentrations
measured against a (heterologous) genotype G virus were shown
to be approximately one half the concentrations measured against
the vaccine strain (genotype A; Jeryl Lynn).17 Thus, antigenic dif-
ferences between wild-type mumps viruses and the mumps vac-
cine strain may further lead to loss of functional mumps
immunity.
Yet our understanding of the natural serologic response
against the mumps virus remains incomplete. Insight is into the
ranges in mumps-specific antibody concentrations, their virus-
neutralization capacity, as well as in the antibody dynamics seen
in time after mumps virus exposure is lacking. The recent epi-
demic of the Netherlands provided an opportunity to evaluate
such aspects of the antibody response following a clinical mumps
virus infection. The course of anti-mumps IgG and virus-neutral-
izing (VN) antibody concentrations in 23 clinical mumps cases
was investigated, 1–2 months and 7–10 months after onset of
disease. Seven of these cases were not MMR vaccinated,
which made it possible to investigate the difference in the
course of antibody response between MMR vaccinated and
unvaccinated persons after recent mumps virus infection. In
addition, a control group was included in the study, to be
able to represent the lower range of anti-mumps antibody
levels as can be expected in healthy (non-infected) vaccinees
that were age–matched. Our study contributes to the under-
standing of how mumps-specific (functional) antibody levels
develop dynamically in vaccinated and unvaccinated mumps
cases in a mumps epidemic setting, relative to maintenance
levels of healthy non-infected vaccinees.
Results
A total of 23 mumps cases and 20 healthy controls partici-
pated in the study. The demographic characteristics, clinical
symptoms of mumps cases, and mumps-specific antibody levels
(IgG concentration and the serum dilution titers resulting in
50% reduction of virus plaques (ND50)) are listed in Table 1.
Four cases of orchitis occurred among the 23 mumps cases; 2 out
of the 7 unvaccinated mumps cases had orchitis, and the other 2
cases of orchitis occurred among the 16 vaccinated mumps cases.
Three mumps cases had complaints that persisted 7–10 months
after onset of disease; 2 of these cases had not been previously
vaccinated.
All participating patients had mumps-specific IgG concentra-
tions far above 45 RU/ml, previously validated as criterion for
seroprevalence for the fluorescent bead-based multiplex IgG
immunoassay (MIA).18 Both vaccinated and unvaccinated
mumps cases had significantly higher geometric mean concentra-
tions (GMC) of mumps-specific IgG at both time points of
sampling (resp 13,617 RU/ml (95% CI of 9,574–19,367 RU/
ml) and 1,552 (445–5412) RU/ml at 1–2 months; 6,514
(5,247–8,088) RU/ml and 1,143 (480–2,725) RU/ml at
7–10 months) than healthy controls (169 (135–210) RU/ml)
(pD 0.001) (Fig. 1A, C, Table 1). The mumps-specific IgG
concentrations of the previously vaccinated mumps cases were
significantly higher within 2 months after onset of disease
(13,617 (9,574–19,367) RU/ml) than at 7–10 months (6,514
(5,247–8,088) RU/ml), whereas the IgG concentrations of the
unvaccinated cases were similar at both time points (resp 1,552
(445–5412) RU/ml at 1–2 months, and 1,143 (480–2,725) RU/
ml at 7–10 months) (Fig. 1A, C, Table 1). The unvaccinated
mumps cases had significantly lower IgG antibody concentra-
tions at both sampling points as compared with cases who had
received 2 doses of the MMR vaccine (Fig. 1A, C). Two out of
the 7 unvaccinated mumps cases had a considerably lower IgG
antibody response 1–2 months than 7–10 months after onset of
disease (Fig. 1C, Table 1).
Patterns in virus-neutralizing (VN) antibody responses
against mumps virus were similar to those observed in total
IgG concentrations, although the variation within the patient
group was less prominent. In agreement with IgG levels, vac-
cinated and unvaccinated mumps cases had significantly
higher ND50 values at both time points of sampling (resp.
Four, 695 (3,779–5,832) RU/ml and 1,533 (832–2,825)
RU/ml at 1–2 months; 2,478 (1,968–3,122) RU/ml and
1,221 (1,029–1,449) RU/ml at 7–10 months) compared with
healthy controls (122 (196–76)) RU/ml) (pD 0.001)
(Fig. 1B). In addition, the anti-mumps ND50 values of the
previously vaccinated mumps cases were higher within
2 months after onset of disease (4,695 (3,779–5,832)
RU/ml) than at 7–10 months (2,478 (1,968–3,122) RU/ml),
whereas the ND50 values of the unvaccinated cases were
similar at both time points (1,533 (832–2,825) RU/ml at 1–
2 months, and 1,221 (1,029–1,449) RU/ml at 7–10 months)
(Fig. 1B). Unvaccinated mumps cases had significantly lower
ND50 values at both sampling points than cases who had
received 2 doses of the MMR vaccine (Fig. 1B, D). Whereas
the variation of the ND50 values among the groups of
mumps cases (vaccinated and unvaccinated groups; sampling
time 1–2 and 7–10 months after onset of disease) was smaller
than the variation in IgG antibody concentrations, the het-
erogeneity of mumps-specific ND50 values among healthy
controls was higher than the IgG concentrations (Fig. 1A, B).
Nevertheless, it must be taken into consideration that healthy
controls were selected based on mumps-specific IgG levels <
500 RU/ml to minimize the risk of recruiting individuals
that had recently been exposed to mumps. The observed
mumps-specific IgG levels of the healthy controls (169
(135–210) RU/ml), appeared to be within the expected range
for this age group as based on other Dutch studies.19,20 The
relationship between the antibody levels measured by multi-
plex immunoassay (MIA) and the virus neutralization assay
appeared to be moderate (r D 0.64; p<0.001) when consid-
ering the samples obtained from the mumps cases exclusively
(Fig. 1E). For the samples of the healthy controls, no
significant relationship (r D 0.34; pD 0.14) was observed. In
the overall data set (n D 64 samples; including all samples
from controls and mumps cases taken at different time
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points) a strong correlation between mumps-specific IgG con-
centrations and ND50 values was found (r D 0.86;
p<0.001). With respect to the mumps cases, no aberrant
antibody response (or trend for lower response) was observed
in cases with orchitis of with persistent complaints (longer
than 7–10 months). Due to the limited number of these
severe cases, statistical analysis was not considered relevant.
Discussion
In the Netherlands, a high overall MMR vaccination coverage
of 96% and 93% for respectively the first and second dose at
14 months- and 9 years-aged children has been reported.21 In a
large cross-sectional cohort (nD7900) of the Dutch population
(2006–2007), it was demonstrated that mumps seroprevalence
Figure 1. Anti-mumps IgG concentrations (A) and ND50 values (B) of the various groups of mumps cases (vaccinated vs. unvaccinated; 1–2 months and
7–10 months after onset of disease) and control group. Dynamics of the anti-mumps IgG concentrations (C) and ND50 values (D) of the vaccinated
mumps cases (closed dots) vs. unvaccinated (open dots) mumps cases at the different time points, i.e. One–2 months and 7–10 months, after onset of
mumps. Correlation (Spearman’s rank analysis) between IgG concentrations and ND50 values of mumps cases (E) Samples from both time points are
included in this analysis; closed symbols represent vaccinated persons and open symbols represent unvaccinated patients; circles represent samples
taken at 1–2 months and triangles represent samples taken at 7–10 months after onset of disease.
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appeared to be 91%, thereby reaching the herd immunity
threshold of 86–92% (i.e. threshold percentages of mumps
herd immunity combined from 2 studies, 86–88%22 and 88–
92%23). A moderate reduction in seroprevalence, i.e., below
or approaching the herd immunity threshold, was observed in
several age groups, including the (vaccinated) age group of
15–21 y19 The relatively low mumps-specific serum antibody
levels in 15–21 year-aged persons confirm the vulnerability of
this group with respect to mumps virus infection, and may
explain the occurrence of the recent epidemic in the Nether-
lands (2009–2012), 5 y after this seroprevalence study. This
epidemic has been described to count a total of 1,254 labora-
tory-confirmed mumps cases. The majority of the mumps
cases was male (59%), university student (47%), 18–25 y of
age (68%), and vaccinated twice with the MMR vaccine
(68%).24,25 In the present study, 2 clear response patterns in
IgG and VN antibody levels against the mumps vaccine strain
could be detected in consecutive blood samples obtained from
mumps virus infected persons during this epidemic. In previ-
ously vaccinated mumps cases, specific IgG concentrations as
well as the ND50 values were significantly higher shortly (1–
2 months) after onset of disease than at 7–10 months. This
pattern in antibody response characterizes a secondary
response, i.e. rapid production of antibodies upon subsequent
encounter with the same antigen. Alternatively, unvaccinated
mumps cases also mounted a seroresponse, but of generally
lower IgG antibody concentrations and ND50 values at both
sampling points than cases who had received 2 MMR vaccine
doses. The overall IgG concentrations or ND50 values of the
unvaccinated cases did not differ significantly between the 2
time points, and 2 out of the 7 unvaccinated mumps cases
had a lower IgG antibody response 1–2 months compared
with 7–10 months after onset of disease. This antibody pat-
tern is illustrative of a primary response. It is striking that 4
out of the 7 unvaccinated mumps cases were aged  40 years,
and it is likely, although not certain, that these persons had
encountered wild-type mumps virus earlier in life. However,
although natural infection with mumps is thought to confer
lifelong protection, incidentally cases of reinfections have been
described,26–28 and with the absence of circulating wild-type
mumps virus also naturally-acquired immunity against mumps
may diminish. In addition, it must be kept in mind that in
our assays antibodies were measured against the mumps vac-
cine strain, which may result in a relatively lower response in
persons with naturally-acquired immunity induced by other
mumps virus strain(s). One of the 2 persons who showed a
rise in mumps-specific IgG antibody level in time, suggestive
of a primary response, was aged >50 years, but the observed
virus-neutralizing (VN) antibody response of this particular
person was not typical for a primary response. VN antibody
concentrations, can be considered a more reliable measure for
protection than total IgG concentrations, as it demonstrates
exclusively the functional part of mumps-specific antibodies.
However, VN antibody assays are more labor-and time-inten-
sive. In the present study, a moderate correlation was found
between the level of IgG antibodies determined by multiplex
immunoassay (MIA) and VN (functional) antibody levels in
the plasma samples derived from the mumps cases (Pearson’s r
D 0.64) (Fig. 1E). No statistical correlation was observed
between the IgG levels and ND50 values in control samples of
healthy persons (Pearson’s r D 0.34). Our results are in agree-
ment with another study among MMR vaccinated university
students and staff, where a similar correlation was found
between IgG and VN antibody levels (Pearson’s r D 0.45).29
In a recent report, the IgG and VN antibody levels (against
whole-mumps virus) also showed a correlation similar to our
results (r D 0.37 and r D 0.66; for samples obtained from
infants at respectively 2 to 4 months after the second MMR
dose and 2 y after the first MMR dose).30 In our study, the
correlation appeared to be stronger over a broad range of anti-
body levels when taking all samples from control subjects and
mumps cases together (Pearson’s r D 0.86).
The study design, i.e., observational study with limited
sample size, did not allow determination of why mumps cases
became infected despite vaccination. Recently, Gouma et al
calculated a provisional cutoff level for protection of mumps-
specific IgG of 243 RU/mL to discriminate between the pre-
outbreak IgG concentrations from infected and non-infected
persons in a large longitudinal serological database of students
over the years 2009–2012.31 Vaccinated mumps cases in our
study might have had pre-exposure levels below this cutoff
value, based on the IgG antibody concentrations of the con-
trol group. Notwithstanding its limited sample size, our
present study describes how mumps-specific antibody concen-
trations and their virus-neutralization capacity develop in
time after mumps virus infection; the antibody response was
significantly higher in the vaccinated mumps cases compared
to the unvaccinated cases at both sampling times, suggestive
of a better and more prolonged immunity against mumps.
Although the humoral response certainly plays a role in pro-
tection against mumps, it should be considered that in vitro
measured VN antibody concentrations, but also IgG concen-
trations, may not be fully predictive of immunological anti-
body activity in vivo, given that Fc-mediated phagocytosis,
antibody-dependent cell-mediated cytotoxicity, and other pro-
cesses that occur in the host are not reflected in the corre-
sponding assays.32 Additionally, other immune mechanisms,
such as cellular immunity, are likely involved in the protec-
tion against mumps disease as well as in the viral clearance.
The cellular immunity against mumps has only been scarcely
explored and deserves more attention.
Summarizing, mumps patients developed high levels of both
mumps-specific IgG concentrations and mumps VN antibodies;
vaccinated patients had higher antibody levels than unvaccinated
patients. Antibody dynamics of vaccinated vs. unvaccinated
mumps cases differed, i.e. vaccinated mumps cases had higher
antibody levels 1–2 months after onset of disease that declined at
7–10 months, which is characteristic of a secondary response.
Previous MMR vaccination resulted in higher (functional) anti-
body levels in the mumps cases, probably by pre-existing B cell
memory, although it was not effective enough to prevent mumps
virus infection.
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Patients and Methods
Subjects and blood sampling
The present observational clinical study was performed
between November 2011 and May 2013 according to EU
Good Clinical Practice guidelines and the principles outlined
in the Helsinki Declaration. Ethical committee approval was
obtained (clinical study number NL37852.094.11) and
informed, written consent was obtained from all participants.
Laboratory-confirmed mumps cases (>18 years) were identi-
fied through the web-based system OSIRIS for national regis-
tration of compulsory notifiable diseases of the Netherlands.
Uninfected age-matched controls (>18 years) were recruited
from contacts of cases, but without symptoms and serological
evidence of mumps disease (mumps-specific IgG levels <500
RU/ml). Selected mumps cases and healthy controls were
approached by telephone and were informed about the nature
of the study before a visit was planned (see Fig. 2 for flow
chart). After giving informed consent, blood samples were
taken, and a small questionnaire was conducted providing
information with regard to basic demographics, vaccination
status, and clinical symptoms of mumps disease. If the vacci-
nation status was indefinite, the status was verified in the
nationwide vaccination registration system (Praeventis). Blood
samples, obtained by venipuncture, were taken from 23 sub-
jects 26 yrs (CI 95% 23–30 yrs) with mumps at 2 time
points after onset of disease. The first samples were taken at
1.3 months (CI 95% 1.2–1.5 months) after the first day of
disease. Convalescent blood samples from these subjects were
taken with an average of 8.8 months (8.3–9.4 months) after
the first day of illness. Seven out of the 23 mumps cases were
unvaccinated and 16 cases were previously vaccinated with 2
doses of the MMR vaccine. In addition, 20 healthy control
persons (25 yrs (22–29 yrs; 35% male) were included who
had no symptoms of mumps or evidence of recent mumps
virus infection based on serologic data. Two out of the 20
healthy controls (aged 55 and 57 years) were unvaccinated,
and 18 controls were previously vaccinated with 2 doses of
the MMR vaccine.
Laboratory procedures
Blood samples, collected in sodium heparin-containing tubes,
were processed within 20 hafter venipuncture. Peripheral blood
mononuclear cells and plasma were separated by density gradient
centrifugation according to manufacturer’s instruction, and
plasma was stored frozen at ¡20C until antibody analysis was
performed.
Mumps-specific IgG concentrations were analyzed using the
mumps vaccine strain (Jeryl Lynn (JL)) as antigen. The fluores-
cent bead-based multiplex immunoassay (MIA) using Luminex
technology was performed as described before.33 Briefly, plasma
samples were diluted 1/200 and 1/4,000 in phosphate buffered
saline containing 0.1% Tween 20 and 3% bovine serum albu-
min. On each plate, controls, blanks and the WHO International
Standard Anti Rubella serum RUBI-1–94 (NIBSC) were
included. The fluorescent intensity of the samples was
Figure 2. Flow chart for subject enrollment.
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interpolated onto the standard curve of the reference serum
(RUBI-1–94) to obtain antibody concentrations, which were
expressed in RIVM units per milliliter (RU/ml) for mumps. An
antibody concentration of 45 RU/ml was used as a criterion for
seroprevalence, as previously described.18 The RIVM units for
mumps used in that assay were standardized against other mumps
standards. RUBI-1–94 has a mumps-specific IgG concentration
of 4384.512 RU/ml and was selected as alternative (internation-
ally-available) standard for mumps, thus enabling comparison
and bridging of our serological data, expressed in RU/ml, to
other studies.31
Mumps virus-neutralizing (VN) antibodies were detected by
focus reduction neutralization test (FRNT), partly based on the
protocol described by Vaidya et al.34 Mumps vaccine virus
(JL strain; stored at ¡80C) was thawed and mixed with heat-
inactivated (45 min 56C) plasma samples (both 37.5 ml) to be
incubated for 2 hat 37C. Culture medium (Dulbecco’s modified
eagle medium (Life Technologies) supplemented with 5% fetal
calf serum, penicillin, streptomycin, and L-glutamine)
was removed from Vero cells (2 £ 104 cells/mL) and 50 ml of
virus/plasma mixture was added to each well of a 96 wells plate
(i.e., > 20 plaques mumps virus per well). Plates were incubated
for 4 hat 36C, wells were emptied and 200 ml of 0.8% carboxy-
methylcellulose medium was added to each well. Plates were
incubated for 40 hat 36C with 5% CO2, before they were
washed with PBS and subsequently fixed with a mixture of aceton
and methanol (2:3). After 10 min, plates were washed with ice-
cold PBS, and incubated with block buffer (PBS containing 1%
BSA) for 30 min at 36C. Anti-mumps nucleoprotein antibody
(Abcam) was in block buffer (1:3000) and 100 ml was added to
each well. After incubation for 1 hat 36C, plates were washed
with PBS containing 0.1% Tween-20 (PBST). Subsequently,
100 ml of goat-anti-mouse IgG-HRP (DAKO) in block buffer
(1:2000) was added to each well and plates were incubated for
one hour at 36C. Plates were washed with PBST and wells were
stained with 50 ml of True Blue peroxidase substrate (KPL, Inc.).
The numbers of plaques were counted and the 50% VN antibody
dose (ND50) of each sample was calculated. The WHO interna-
tional standard RubI-1–94 (NIBSC) was used as positive control
in each assay run and to calculate relative ND50 value in order to
adjust for inter-assay differences.
Statistics
Age, intervals between sampling and disease, and antibody
concentrations were described as geometric mean with lower and
upper 95% confidence intervals (95% CI). IgG concentrations
and ND50 values of healthy controls vs. mumps cases, and vacci-
nated vs. unvaccinated mumps cases at both sampling time
points were compared with the nonparametric Mann Whitney
U test (for independent samples). IgG concentrations and ND50
values of vaccinated mumps cases determined from samples taken
at 1–2 months vs. Seven–10 months after disease onset were ana-
lyzed with the nonparametric Wilcoxon signed rank test for
related samples. Correlation between IgG concentrations and
ND50 values of different sampling groups, as well as for all sam-
ples together, was performed with the nonparametric Spearman’s
rank analysis. For all statistical analysis, -values p-values <0.05
were considered statistically significant. Data were analyzed with
IBM SPSS Statistics version 19.0.
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